The U.S. Food and Drug Administration’s Office of Compliance has recently unveiled its Annual Report for Fiscal Year 2023, spotlighting significant strides and ongoing efforts in the realm of drug compounding and the implementation of the Drug Quality and Security Act (DQSA). As we mark nearly a decade since the enactment of DQSA, the emphasis...